
Objective This study assessed pre-injection anxiety, compared pre- and post-injection anxiety, evaluated recalled first-injection anxiety, and identified factors associated with anxiety and post-injection stated willingness to receive supportive assistance during future intravitreal injections (IVIs). Methods and analysis In this multicentre prospective observational study, 480 adults undergoing IVI in Palestine assessed their anxiety immediately before and after injection using a five-level pictorial ordinal rating item anchored to predefined ranges on a 0–10 numeric anxiety scale. All 480 participants had undergone at least one IVI before the current study visit and retrospectively rated their anxiety during their first-ever IVI using the same five-category item. After the current injection, stated willingness to receive supportive assistance during future injections was assessed using a Likert-type item. Non-parametric paired tests were used to compare anxiety assessments. Associations were examined using restricted partial proportional-odds regression for pre-injection anxiety, ordinal logistic regression for three-level supportive-care preference, and binary logistic sensitivity analyses. Additional sensitivity models incorporated recruitment-centre fixed effects. Results Median age was 63 years (IQR: 56-68), and 246 patients (51.2%) were female. Median pre-injection anxiety was category 3 (IQR: 2-3), with 82 participants (17.1%) selecting the two highest anxiety categories. Post-injection anxiety was significantly lower than pre-injection anxiety (median category: 2, IQR: 2-2 vs. 3, IQR: 2-3; p < 0.001). Participants recalled greater anxiety during their first-ever IVI than they reported immediately before the current IVI (median category 4 [IQR 3–4] vs 3 [IQR 2–3]; paired p < 0.001). In the restricted partial proportional-odds model, female sex was associated with higher pre-injection anxiety (aOR = 2.64, 95% CI 1.86–3.74), whereas associations involving diabetic retinopathy and previous injection history varied across anxiety thresholds. Following injection, 216 participants (45.0%) agreed with the item concerning hypothetical support during future IVIs. Higher pre-injection anxiety was associated with more favourable post-injection stated willingness (aOR = 1.50 per anxiety category, 95% CI 1.24–1.81). Conclusions Pre-injection anxiety varied among IVI patients and decreased after the procedure. Higher anxiety was associated with greater willingness to receive supportive care. These findings highlight the importance of routinely addressing patients' procedural concerns and offering additional supportive measures according to individual preferences. Further interventional studies are needed to evaluate the effectiveness of such measures.
Background Current evidence on continuous labetalol infusion for blood pressure (BP) control in spontaneous intracerebral hemorrhage (SICH) is limited with unclear information on higher doses. Objectives To evaluate the effectiveness and safety of continuous labetalol in SICH patients. Methods We conducted a prospective, single-arm observational study involving SICH patients who received continuous labetalol infusion to achieve and maintain target BP (<140/90 mmHg). Effective outcomes included BP control, the time required to achieve the target BP, BP variability, and hematoma expansion. Safety outcomes included adverse event (AE) rates and predictive factors. Subgroup analyses were performed by categorizing patients into low (≤300 mg) and high (>300 mg) cumulative dose groups within 24 hours. Results A total of 84 patients were available for analysis. The median time to reach target BP was 2.0 hours (interquartile range, IQR: 0.5–3.3 hours), and the median percentage of time at target BP was 53% (IQR: 35–66%). The BP profile suggested stable BP control over 24 hours. Hematoma expansion was observed in 8.3% of patients. During continuous labetalol infusion, 42 AEs were reported in 19 patients, with bradycardia being the most common (22.6%). However, no resuscitation was required. The incidence of bradycardia or hypotension appeared to be comparable between the low and high cumulative dose groups. Predictive factors for AEs included baseline systolic BP (SBP), baseline heart rate (HR), and diabetes, all having an inverse relationship with the probability of AEs. Conclusion Continuous labetalol infusion provides effective and sustained BP control in SICH, with an acceptable safety profile at cumulative doses exceeding 300 mg. Lower baseline SBP and HR were associated with a higher risk of AEs and may help identify patients requiring closer monitoring.The study was registered with the Thai Clinical Trials Registry (TCTR20240423003) and can be accessed at https://www.thaiclinicaltrials.org/show/TCTR20240423003.
Objective SCT630 is a recombinant fully human anti-TNF-α IgG1 monoclonal antibody developed as a biosimilar to adalimumab reference product Humira® (AbbVie). This study aims to evaluate the pharmacokinetic (PK) similarity, characterize pharmacokinetics between healthy participants and patients, and identify potential sources of PK variability of SCT630 and Humira® using population pharmacokinetic modeling approach. Methods A population pharmacokinetic model was developed using PK data from a phase I study in healthy participants and a phase III study in patients with moderate to severe plaque psoriasis (PsO). Results A one-compartment PopPK model with first-order linear elimination adequately described SCT630 and Humira® concentration data. The covariates analysis identified anti-drug antibody, body weight, total bilirubin, alanine aminotransferase, participant type and study drug as significant covariates affecting clearance and volume of distribution. Model-predicted exposures, including Cmax and AUC were obtained, and their geometric mean ratios (test versus the reference group) were calculated. The 90% confidence intervals (CI) for all these ratios fell entirely within the range of 80.00% to 125.00%. Conclusion This analysis integrated data from both healthy participants and patients with PsO, and provided a valuable assessment of adalimumab PK characteristics and significant covariates. This model-based approach further elucidates how the SCT630 PK profile compares to that of Humira® in healthy participants and patients with PsO, supporting the totality-of-evidence for the biosimilarity of SCT630.
Background COVID-19 frequently presents with pneumonia. Impaired immune function, particularly in older adults and immunocompromised individuals, increases susceptibility to infection and contributes to higher morbidity and mortality. Among inflammatory cytokines, Interleukin-6 (IL-6) plays a pivotal role in immune dysregulation and cytokine storm. Therefore, this study aimed to investigate the association between serum IL-6 levels and clinical, laboratory, radiological, and outcome-related findings among hospitalized patients with COVID-19. Methods This descriptive-analytical cross-sectional study included 210 hospitalized COVID-19 patients at Shahid Beheshti Hospital, Kashan. Serum IL-6 was measured as part of their diagnostic and therapeutic workup. Demographic characteristics, clinical manifestations, laboratory markers, imaging findings, and outcomes were recorded. Patients with incomplete data were excluded. Data were analyzed using SPSS software version 26. Results The mean age of patients was 50.37 ± 17.48 years, with a slight male predominance (51%). Hypertension was the most common comorbidity (31.9%). Abnormal laboratory markers included elevated LDH (64.3%), ESR (61.0%), lymphopenia (59.5%), and CRP (58.6%). Pulmonary involvement on CT was noted in 91.5% of patients, with moderate involvement most frequent (41.4%). ICU admission occurred in 17.1% and mechanical ventilation was required in 10.5%. The mean CALL score was 8.63 ± 2.33, and average hospital stay was 6.70 ± 5.27 days. Serum IL-6 levels were significantly associated (P < 0.05) with age, oxygen saturation, lymphopenia, LDH, CRP, CT involvement, disease severity, ICU admission, mortality, and length of hospitalization. Conclusion Elevated serum IL-6 strongly reflects disease severity and adverse outcomes in COVID-19, highlighting its potential as a prognostic biomarker to guide clinical assessment and management.
Introduction Delayed subcutaneous (SC) insulin absorption remains one of the major barriers to optimal blood glucose control in people with type 1 diabetes and to the development of a fully automated artificial pancreas with SC insulin delivery. Our recent proof of concept study demonstrated that injecting 0.1 mg glucagon at the SC insulin (NovoRapid®) injection site enhances insulin absorption in a porcine model. Present experiments investigate the pharmacokinetics of Lyumjev®, the fastest-acting insulin currently available, when micro-doses of glucagon are co-injected at the same SC site. Methods 20 anesthetized pigs were administered 10 IU of Lyumjev® SC. Animals were assigned to either a glucagon group (n = 12), receiving micro-doses of glucagon at the same subcutaneous injection site as insulin, or a control group (n = 8), receiving Lyumjev® only. Arterial blood samples were collected over a 210-minute period to measure glucose, insulin, and glucagon concentrations. Results Compared with Lyumjev® alone, the addition of glucagon to Lyumjev® was associated with an approximately 21% higher mean Cmax (58 vs 48 mU/L) and a 17% earlier Tmax (25 vs 30 min). Early insulin exposure increased by 109% during the first 15 minutes and by 60% during the first 30 minutes following the addition of glucagon to Lyumjev® compared with Lyumjev® alone (AUC₀–₁₅: 654 vs 313 mU·min/L and AUC₀–₃₀: 1506 vs 942 mU·min/L, respectively). Conclusion These experiments in pigs suggest that micro-amounts of glucagon, when injected at the same SC site as insulin, may speed up and enhance the early absorption of a single SC insulin bolus.